With almost all G-protein-coupled receptors (GPCRs) within the body controlled by just two arrestin proteins, β-arrestin 1 and β-arrestin 2, the emerging importance of arrestins in executing the downstream functions of GPCRs has captured the interest of those working in drug discovery.
Yet the diverse nature of these mechanisms makes the β-arrestins challenging targets for modulating the downstream effects of GPCR activity.
- The therapeutic potential of GPCR-β-arrestin interactions
- Details on recent β-arrestin research and suggestions on future directions
- Insights into the tools that support β-arrestin research and drug discovery